[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639431":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":11,"centralContacts":33,"locations":39,"responsibleParty":55,"collaborators":11,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":11,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":11,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":11,"overallStatus":76,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Asan Medical Center","OTHER",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"High-dose group","EXPERIMENTAL",null,[13],"Biological: umbilical cord-derived mesenchymal stem cell",{"label":15,"type":10,"description":11,"interventionNames":16},"Medium-Dose Group",[13],{"label":18,"type":19,"description":11,"interventionNames":20},"Placebo Comparator","PLACEBO_COMPARATOR",[21],"Drug: Normal Saline",[23,28],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"BIOLOGICAL","umbilical cord-derived mesenchymal stem cell","Administration of high-dose or medium-dose umbilical cord-derived mesenchymal stem cells",[9,15],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"DRUG","Normal Saline","Administration of normal saline as a placebo control.",[18],[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Kyoung Hwan Koh","CONTACT","+82-2-3010-3530","osdoc.koh@gmail.com",[40],{"facility":5,"status":11,"city":41,"state":41,"zip":42,"country":43,"countryCode":11,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Seoul","05505","South Korea",{"type":45,"coordinates":46},"Point",[47,48],126.9784,37.566,{"lat":48,"lon":47},[51],{"name":52,"role":36,"phone":53,"phoneExt":11,"email":54},"Sarah Hwang","+82-2-3010-8674","tpfkzlxl@naver.com",{"type":56,"investigatorFullName":35,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Principal Investigator","100639431","umbilical-cord-derived-mesenchymal-stem-cell-injectables-for-the-regeneration-of-partial-thickness-rotator-cuff-tears-100639431",false,"NCT07605559","Umbilical Cord-derived Mesenchymal Stem Cell Injectables for the Regeneration of Partial-thickness Rotator Cuff Tears","A Multi-center Study on Umbilical Cord-derived Mesenchymal Stem Cell Injectables for the Regeneration of Partial-thickness Rotator Cuff Tears","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Shoulder pain lasting for at least 3 months\n* A pain visual analogue scale (VAS) score of 4 or greater\n* Inadequate response to sufficient conservative treatment for at least 3 months, such as medication, injection therapy, physical therapy, or exercise therapy\n* Partial-thickness rotator cuff tear confirmed by ultrasonography or magnetic resonance imaging (MRI)\n* No restrictions on participation in clinical trial procedures, including hospitalization\n\nExclusion Criteria:\n\n* Receipt of subacromial injection therapy in the affected shoulder within the past 3 months\n* History of rotator cuff surgery on the affected shoulder within the past 6 months\n* Previous treatment with a stem cell therapy for the shoulder\n* Presence of any of the following shoulder conditions: full-thickness rotator cuff tear, obvious isolated acromioclavicular joint arthropathy, or a clear history of trauma to the shoulder joint within the past 3 months\n* Radiologic findings suggestive of or consistent with any of the following: malignancy, severe glenohumeral osteoarthritis, bony abnormalities causing narrowing of the subacromial space, or clear evidence of acute traumatic rotator cuff injury\n* Presence of symptomatic cervical spine disease\n* Patients with polyarthritis, infectious arthritis, rheumatoid arthritis, or fibromyalgia\n* Clinical trial subjects with neurological deficits\n* Pregnant or breastfeeding women\n* Unwillingness to use an effective method of contraception during participation in the clinical trial\n* Presence of any serious disease that may affect participation in this clinical trial, including cardiovascular, renal, hepatic, endocrine, or neoplastic disease\n* Inability to understand the questions used to assess the subject's condition, including the visual analogue scale (VAS), or communication difficulties due to psychiatric illness\n* Unwillingness to participate in the clinical trial or difficulty in complying with follow-up visits according to the study schedule\n* Participation in another clinical trial within 3 months prior to enrollment in this clinical trial\n* Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this clinical trial","ALL","19 Years",{"count":68,"type":69},38,"ESTIMATED","INTERVENTIONAL",[72],"NA","The purpose of this study is to evaluate umbilical cord-derived mesenchymal stem cell injectables for the regeneration of partial-thickness rotator cuff tears",[75],"Rotator Cuff Disease","NOT_YET_RECRUITING","2026-05-18",{"date":79,"type":80},"2026-05-26","ACTUAL",{"date":82,"type":69},"2026-05-01",{"date":84,"type":69},"2028-12-31",{"name":35,"class":6},1]